BACKGROUND AND AIMS
Background: the roots of immune-related adverse events inequalities between female and male cancer patients
In patients with cancer, the increasing use of immunotherapic treatments is associated with immune-related adverse events (irAEs) caused by non-specific activation of the immune system. IrAEs usually develop within the first few weeks to 6 months after treatment initiation; however, they can also present after cessation of immunotherapic treatment. Sex influences the adaptive immunity, and may influence irAEs types, frequency and severity. Accumulating evidences support the existence of sex-driven differences in immune responses as potential factors contributing to disease outcome and response to therapy. Together with genetic and biological differences, the roots of irAEs inequalities between female and male patients could also be linked to psycho-social and behavioral determinants.
More information on the http://gender-net-plus.eu/
The contents of this website and the view expressed in the news and publications are the sole responsibility of the authors and under no circumstances can be regarded as reflecting the position of the European Union Send us an email: firstname.lastname@example.org
Copyright © 2020 G-DEFINER | Powered by G-DEFINER
Graphics for this website have been provided by the G-DEFINER Consortium Partners. No part of this website may be used, Reproduced and/or disclosed in any form or by any means without the prior written permission of the G-DEFINER Consortium Partners